

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



美瑞健康国际产业集团

Meilleure Health International Industry Group

MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED

美瑞健康國際產業集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 2327)

**POSITIVE PROFIT ALERT
SUBSTANTIAL GROWTH IN PROFIT**

This announcement is made by Meilleure Health International Industry Group Limited (the “**Company**” and, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors of the Company that based on the preliminary review of the unaudited consolidated management accounts of the Company and its subsidiaries (the “**Group**”) for the year ended 31 December 2017 (the “**Reporting Period**”) and the information currently available, it is expected to record an increase ranging from 80% to 150% in the profit attributable to the owners of the Company for the year ended 31 December 2017 as compared to that for the year ended 31 December 2016.

The expected significant increase of profit during the year is mainly attributable to the steady growth of medical and health management business, consultancy business and trading business, among which revenue from consultancy and advisory business recorded growth, with a significant increase of over ten times in net profit. In addition, the fair value of the investment properties held for trading for the Group increases notably.

The information contained in this announcement is only based on the preliminary assessment of the Board based on the unaudited consolidated financial information of the Group for the Reporting Period, which is subject to the audit or review by the auditor of the Company and may be amended. Detailed financial information will be disclosed in the final result announcement for the Reporting Period of the Group, which is expected to be released by the end of March 2018.

Holders of the Company's shares and securities and potential investors are advised to exercise caution when dealing in the shares and securities of the Company.

By Order of the Board
Meilleure Health International Industry Group Limited
Zhou Wen Chuan
Chief Executive Officer

Hong Kong, 20 February 2018

As at the date of this announcement, the Board comprises Mr. Zhou Xuzhou, Mr. Liu Lailin and Ms. Zhou Wen Chuan as executive Directors, Dr. Mao Zenhua as non-executive Director and Mr. Gao Guanjiang, Professor Chau Chi Wai, Wilton and Mr. Zeng Wentao as independent non-executive Directors.